Entasis Therapeutics Holdings Inc. (ETTX) symbol metrics page

Entasis Therapeutics Holdings Inc. (ETTX) NASDAQ

$2.19 - (-)

Market Cap: -

As of 07/08/22 12:00 AM EDT. Market closed.

Entasis Therapeutics Holdings Inc. (ETTX)
NASDAQ

$2.19
- (-)

Market Cap: -

As of 07/08/22 12:00 AM EDT. Market closed.

Add to Portfolio

Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), ... read more

COMPANY PROFILE

Sector

Manufacturing

Industry

Pharmaceutical Preparation Manufacturing

URL

entasistx.com

Address

Sector

Manufacturing

Industry

Pharmaceutical Preparation Manufacturing

Full Time Employees

URL

entasistx.com

Address

PRICE CHART FOR ENTASIS THERAPEUTICS HOLDINGS INC

YTD

MAX

From: To:

NEWS

INSIDEARBITRAGE ARTICLES

KEY STATS

Open

Previous Close

$2.19

Days Range

$2.19 - $2.20

52 week range

- - -

Volume

Avg. Volume (30 days)

Market Cap

Dividend Yield

P/E

Shares Outstanding

47,851,779

Open

Previous Close

$2.19

Days Range

$2.19 - $2.20

52 week range

- - -

Volume

Avg. Volume (30 days)

Market Cap

Dividend Yield

P/E

Shares Outstanding

47,851,779

FINANCIAL STATEMENTS FOR ENTASIS THERAPEUTICS HOLDINGS INC

Open in:

INSIDER TRANSACTIONS FOR ENTASIS THERAPEUTICS HOLDINGS INC

Owner	Relationship	Date	Transaction	Cost	# Shares	Value($)	Total Shares	Form 4
Innoviva, Inc.	10% Owner	Jul 11, 2022	Buy	$2.20	7,598,814	16,717,391	29,270,476	Jul 13, 2022, 09:27 PM
Innoviva, Inc.	10% Owner	Jul 08, 2022	Buy	$2.20	11,671,662	25,677,657	21,671,662	Jul 13, 2022, 09:27 PM
Tommasi Ruben	Chief Scientific Officer	Jul 07, 2022	Option Exercise	$2.20	39,596	87,111	0	Jul 11, 2022, 04:09 PM
Ronsheim Matthew	Chief of Pharma Sciences & MFG	Jul 07, 2022	Option Exercise	$2.20	17,572	38,658	0	Jul 11, 2022, 04:09 PM
Perros Manoussos	President and CEO	Jul 07, 2022	Option Exercise	$2.20	56,072	123,358	0	Jul 11, 2022, 04:08 PM
Mueller John Patrick	Chief Development Officer	Jul 07, 2022	Option Exercise	$2.20	17,092	37,602	0	Jul 11, 2022, 04:07 PM
Meek David D.	Director	Jul 11, 2022	Option Exercise	$2.20	27,500	60,500	0	Jul 11, 2022, 04:07 PM
Meek David D.	Director	Jul 07, 2022	Option Exercise	$2.20	22,000	48,400	0	Jul 11, 2022, 04:07 PM
Mayer Howard	Director	Jul 11, 2022	Option Exercise	$2.20	27,500	60,500	0	Jul 11, 2022, 04:06 PM
Mayer Howard	Director	Jul 07, 2022	Option Exercise	$2.20	22,000	48,400	0	Jul 11, 2022, 04:06 PM
Keiley Elizabeth M	General Counsel	Jul 07, 2022	Option Exercise	$2.20	17,572	38,658	0	Jul 11, 2022, 04:06 PM
HASTINGS DAVID C	Director	Jul 11, 2022	Option Exercise	$2.20	27,500	60,500	0	Jul 11, 2022, 04:05 PM
HASTINGS DAVID C	Director	Jul 07, 2022	Option Exercise	$2.20	22,000	48,400	0	Jul 11, 2022, 04:05 PM
Berger Heather A.	Director	Jul 11, 2022	Option Exercise	$2.20	27,500	60,500	0	Jul 11, 2022, 04:04 PM
Berger Heather A.	Director	Jul 07, 2022	Option Exercise	$2.20	22,000	48,400	0	Jul 11, 2022, 04:04 PM
Altarac David	Chief Medical Officer	Jul 07, 2022	Option Exercise	$2.20	17,572	38,658	0	Jul 11, 2022, 04:03 PM
Ronsheim Matthew	Chief, Pharma Sciences & MFG.	Nov 02, 2021	Option Exercise	$2.94	3,669	10,787	42,572	Nov 03, 2021, 04:05 PM
Keiley Elizabeth M	General Counsel	Nov 02, 2021	Option Exercise	$2.94	3,669	10,787	42,572	Nov 03, 2021, 04:04 PM
Altarac David	Chief Medical Officer	Nov 02, 2021	Option Exercise	$2.94	3,669	10,787	42,572	Nov 03, 2021, 04:04 PM
Mueller John Patrick	Chief Development Officer	Nov 02, 2021	Option Exercise	$2.94	3,907	11,487	42,092	Nov 03, 2021, 04:03 PM
Perros Manoussos	President and CEO	Nov 02, 2021	Option Exercise	$2.94	11,704	34,410	135,822	Nov 03, 2021, 04:03 PM
Gutch Michael	CFO and Chief Business Officer	Nov 02, 2021	Option Exercise	$2.94	3,669	10,787	42,572	Nov 03, 2021, 04:02 PM
Tommasi Ruben	Chief Scientific Officer	Nov 02, 2021	Option Exercise	$2.94	3,669	10,787	64,596	Nov 03, 2021, 04:02 PM
Perros Manoussos	See Remarks	Oct 19, 2021	Sale	$3.19	11,974	38,197	147,526	Oct 20, 2021, 04:14 PM
Mueller John Patrick	Chief Development Officer	Oct 19, 2021	Sale	$3.19	4,001	12,763	45,999	Oct 20, 2021, 04:10 PM
Gutch Michael	See Remarks	Oct 19, 2021	Sale	$3.19	3,759	11,991	46,241	Oct 20, 2021, 04:09 PM
Tommasi Ruben	Chief Scientific Officer	Oct 19, 2021	Sale	$3.19	3,759	11,991	68,265	Oct 20, 2021, 04:08 PM
Keiley Elizabeth M	General Counsel	Oct 19, 2021	Sale	$3.19	3,759	11,991	46,241	Oct 20, 2021, 04:08 PM
Altarac David	Chief Medical Officer	Oct 19, 2021	Sale	$3.19	3,759	11,991	46,241	Oct 20, 2021, 04:06 PM
Ronsheim Matthew	See Remarks	Oct 19, 2021	Sale	$3.19	3,759	11,991	46,241	Oct 20, 2021, 04:05 PM
Innoviva, Inc.	10% Owner	Sep 01, 2020	Buy	$2.67	4,672,897	12,499,999	18,672,897	Sep 01, 2020, 05:31 PM
Innoviva, Inc.	10% Owner	Jun 11, 2020	Buy	$2.50	12,677,490	31,693,725	14,000,000	Jun 12, 2020, 05:34 PM
Frazier Life Sciences VIII, L.P.	10% Owner	Jan 09, 2020	Sale	$5.00	50,000	250,010	1,299,953	Jan 13, 2020, 10:47 AM
Tommasi Ruben	Chief Scientific Officer	Dec 21, 2018	Option Exercise	$3.45	22,024	75,921	22,024	Dec 26, 2018, 04:45 PM
Topper James N	Director	Sep 28, 2018	Buy	$15.00	375,887	5,638,305	1,349,953	Oct 02, 2018, 09:42 PM
Sofinnova Venture Partners IX, L.P.	10% Owner	Sep 28, 2018	Buy	$15.00	337,724	5,065,860	1,180,178	Oct 02, 2018, 09:41 PM
Preston Heather	Director	Sep 28, 2018	Buy	$15.00	337,724	5,065,860	1,180,178	Oct 02, 2018, 09:40 PM
Pivotal bioVenture Partners Fund I, L.P.	10% Owner	Sep 28, 2018	Buy	$15.00	337,724	5,065,860	1,180,178	Oct 02, 2018, 09:39 PM
GALAKATOS NICHOLAS	Director	Sep 28, 2018	Buy	$15.00	453,395	6,800,925	1,623,405	Oct 02, 2018, 09:38 PM
Frazier Life Sciences VIII, L.P.	10% Owner	Sep 28, 2018	Buy	$15.00	375,887	5,638,305	1,349,953	Oct 02, 2018, 09:38 PM
Clarus Lifesciences III, L.P.	10% Owner	Sep 28, 2018	Buy	$15.00	453,395	6,800,925	1,623,405	Oct 02, 2018, 09:36 PM
ASTRAZENECA PLC	10% Owner	Sep 28, 2018	Buy	$15.00	246,666	3,699,990	2,164,855	Oct 02, 2018, 09:35 PM
TPG Group Holdings (SBS) Advisors, Inc.	Former 10% Owner	Sep 28, 2018	Buy	$15.00	262,539	3,938,085	1,020,748	Oct 02, 2018, 04:46 PM
Novo Holdings A/S	10% Owner	Sep 28, 2018	Buy	$15.00	1,089,835	16,347,525	2,181,843	Oct 01, 2018, 04:36 PM

Load More Insider Transactions

Buy Sale Option Exercise

Owner	Relationship	Date	Value($)
Innoviva, Inc.	10% Owner	07/11/2022	16,717,391
Innoviva, Inc.	10% Owner	07/08/2022	25,677,657
Tommasi Ruben	Chief Scientific Officer	07/07/2022	87,111
Ronsheim Matthew	Chief of Pharma Sciences & MFG	07/07/2022	38,658
Perros Manoussos	President and CEO	07/07/2022	123,358
Mueller John Patrick	Chief Development Officer	07/07/2022	37,602
Meek David D.	Director	07/11/2022	60,500
Meek David D.	Director	07/07/2022	48,400
Mayer Howard	Director	07/11/2022	60,500
Mayer Howard	Director	07/07/2022	48,400
Keiley Elizabeth M	General Counsel	07/07/2022	38,658
HASTINGS DAVID C	Director	07/11/2022	60,500
HASTINGS DAVID C	Director	07/07/2022	48,400
Berger Heather A.	Director	07/11/2022	60,500
Berger Heather A.	Director	07/07/2022	48,400
Altarac David	Chief Medical Officer	07/07/2022	38,658
Ronsheim Matthew	Chief, Pharma Sciences & MFG.	11/02/2021	10,787
Keiley Elizabeth M	General Counsel	11/02/2021	10,787
Altarac David	Chief Medical Officer	11/02/2021	10,787
Mueller John Patrick	Chief Development Officer	11/02/2021	11,487
Perros Manoussos	President and CEO	11/02/2021	34,410
Gutch Michael	CFO and Chief Business Officer	11/02/2021	10,787
Tommasi Ruben	Chief Scientific Officer	11/02/2021	10,787
Perros Manoussos	See Remarks	10/19/2021	38,197
Mueller John Patrick	Chief Development Officer	10/19/2021	12,763
Gutch Michael	See Remarks	10/19/2021	11,991
Tommasi Ruben	Chief Scientific Officer	10/19/2021	11,991
Keiley Elizabeth M	General Counsel	10/19/2021	11,991
Altarac David	Chief Medical Officer	10/19/2021	11,991
Ronsheim Matthew	See Remarks	10/19/2021	11,991
Innoviva, Inc.	10% Owner	09/01/2020	12,499,999
Innoviva, Inc.	10% Owner	06/11/2020	31,693,725
Frazier Life Sciences VIII, L.P.	10% Owner	01/09/2020	250,010
Tommasi Ruben	Chief Scientific Officer	12/21/2018	75,921
Topper James N	Director	09/28/2018	5,638,305
Sofinnova Venture Partners IX, L.P.	10% Owner	09/28/2018	5,065,860
Preston Heather	Director	09/28/2018	5,065,860
Pivotal bioVenture Partners Fund I, L.P.	10% Owner	09/28/2018	5,065,860
GALAKATOS NICHOLAS	Director	09/28/2018	6,800,925
Frazier Life Sciences VIII, L.P.	10% Owner	09/28/2018	5,638,305
Clarus Lifesciences III, L.P.	10% Owner	09/28/2018	6,800,925
ASTRAZENECA PLC	10% Owner	09/28/2018	3,699,990
TPG Group Holdings (SBS) Advisors, Inc.	Former 10% Owner	09/28/2018	3,938,085
Novo Holdings A/S	10% Owner	09/28/2018	16,347,525

Load More Insider Transactions

BUYBACK ANNOUNCEMENT(S) FOR ENTASIS THERAPEUTICS HOLDINGS INC

Active Completed

Looking for more premium content?